Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04329923 · ClinicalTrials.gov registry record · Phase 2
The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)
A Phase 2 study, sponsored by Ravi Amaravadi, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 173
- Enrollment target
NCT04329923: Clinical Trial Phase 2 study, sponsored by Ravi Amaravadi, MD.
NCT04329923 is a Phase 2 study that was terminated before completion, run by Ravi Amaravadi, MD. The registered enrollment target is 173 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04329923, a Phase 2 study, was terminated before completion, sponsored by Ravi Amaravadi, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 173 participants
- Enrollment target
Study Summary
The PATCH trial (Prevention And Treatment of COVID-19 with Hydroxychloroquine) is funded investigator-initiated trial that includes 3 cohorts. Cohort 1: a double-blind placebo controlled trial of high dose HCQ as a treatment for home bound COVID-19 positive patients; Cohort 2: a randomized study testing different doses of HCQ in hospitalized patients; Cohort 3: a double blind placebo controlled trial of low dose HCQ as a preventative medicine in health care workers.
Primary Outcome
Cohort 1 (home quarantined COVID-19 patients): Median time to release from quarantine by meeting the following criteria: 1) No fever for 72 hours 2) improvement in other symptoms and 3) 7 or 10 days (depending on CDC guidance at the time) have elapsed since the beginning of symptom onset.
Interventions
- DRUG Placebo oral tablet
- DRUG Hydroxychloroquine Sulfate 400 mg twice a day
- DRUG Hydroxychloroquine Sulfate 600 mg twice a day
- DRUG Hydroxychloroquine Sulfate 600 mg once a day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2020-04-09 |
| Est. Completion | 2020-11-13 |
| Phase | Phase 2 |
Why NCT04329923 stopped before completion
NCT04329923 is an interventional study that assigns participants to a tested intervention. The registered 173 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo oral tablet is the first listed.
NCT04329923 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04329923 about?
NCT04329923 is a clinical study titled "The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)". The PATCH trial (Prevention And Treatment of COVID-19 with Hydroxychloroquine) is funded investigator-initiated trial that includes 3 cohorts. Cohort 1: a double-blind placebo controlled trial of high dose HCQ as a treatment for home bound COVID-19 positive patients; Cohort 2: a randomized study tes...
What is the current status of trial NCT04329923?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 173 participants. The study started on 2020-04-09. Estimated completion is 2020-11-13.
What interventions are being tested in trial NCT04329923?
The interventions under investigation include: Placebo oral tablet (DRUG), Hydroxychloroquine Sulfate 400 mg twice a day (DRUG), Hydroxychloroquine Sulfate 600 mg twice a day (DRUG), Hydroxychloroquine Sulfate 600 mg once a day (DRUG).
Who is sponsoring clinical trial NCT04329923?
This trial is sponsored by Ravi Amaravadi, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04329923's enrollment target sits among peer trials
173 397th of 2000 higher than 1,604 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05568719 · 173 participants · Phase 3
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- NCT07070115 · 173 participants · NA
Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®
- NCT07150832 · 173 participants · NA
Efficacy of the I-CARE Digital Health Intervention
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI